Form 4: Compass Therapeutics' Chief Accounting Officer, Neil Lerner, Increases Stake with $28,400 Stock Purchase

Neil Lerner, Chief Accounting Officer of Compass Therapeutics, recently acquired 20,000 shares of common stock at an average price of $1.42 per share, increasing his direct holdings in the company.

Summary

• On April 7, 2025, Neil Lerner, the Chief Accounting Officer of Compass Therapeutics, Inc. (CMPX), purchased 20,000 shares of the company's common stock.
• The shares were acquired at a weighted average price of $1.42 per share.
• The total value of the purchase was approximately $28,400.
• Following the transaction, Lerner directly owns 320,000 shares of Compass Therapeutics.
• The purchase was made directly by Lerner.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports an insider stock purchase, which can be interpreted as mildly positive but doesn't provide strong evidence for a bullish or bearish outlook.

Positives

• The purchase of shares by a company officer can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future performance. This purchase by the Chief Accounting Officer could be interpreted as a positive sign, but should be considered alongside other factors when evaluating Compass Therapeutics.

Stakeholder Impact

• The stock purchase could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Compass Therapeutics, CMPX, Neil Lerner, insider trading, stock purchase, Chief Accounting Officer, Form 4, beneficial ownership